Did animal offer relevant model for Bevacizumab testing? - Wikidata - awgldk - TriplyDB

Did animal offer relevant model for Bevacizumab testing?

Did animal offer relevant model for Bevacizumab testing?

http://www.wikidata.org/entity/Q43245707

about

Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.

P2860

Q44916496-D91DD8B7-647C-48DF-82C1-3B394F964E96

P2860

Did animal offer relevant model for Bevacizumab testing?

http://www.wikidata.org/entity/Q43245707

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Did animal offer relevant model for Bevacizumab testing?

@en

Did animal offer relevant model for Bevacizumab testing?

@nl

type

label

Did animal offer relevant model for Bevacizumab testing?

@en

Did animal offer relevant model for Bevacizumab testing?

@nl

prefLabel

Did animal offer relevant model for Bevacizumab testing?

@en

Did animal offer relevant model for Bevacizumab testing?

@nl

P1433

Q43245707-044191DC-08E9-4099-8FE4-51DCC3CB850C

P1476

Q43245707-BDD94239-0D31-4E6D-8F06-65D2B4CE531A

P2093

Q43245707-2ACBB2F9-5D47-4DDD-B5CD-7978DC7D70E1

Q43245707-5D4AA20B-41B3-44D7-953F-6FED561C845D

Q43245707-B3033DC0-81D4-4D8D-A401-08338508101E

Q43245707-C89B43A4-0392-41BE-8CA8-0B1539A3490E

P2860

Q43245707-625D8AFF-722F-4968-BD47-9F6300861CE2

Q43245707-6A3FB5B1-BACF-4CBD-B57D-452BFC88F239

Q43245707-73578235-8EB0-4068-A968-02DCBB3BEFF6

Q43245707-C78FA8CD-B11A-4841-B9D0-54588A1AC01A

Q43245707-EC889EAD-FB55-444A-A2AD-72E118811C52

P2888

Q43245707-335A6563-43FD-48C5-B5B3-963B2A428332

P304

Q43245707-C096414B-F92A-406D-8814-F2E1B64ED3F5

P31

Q43245707-2E3DD34D-F7DB-411A-BFF7-088C3E9D35D2

P356

Q43245707-99AFE802-E32E-4D2F-A0E4-BB7BC55D4463

P407

Q43245707-AA39F555-ACE6-460E-8CC3-A4C4A501DFCE

P433

Q43245707-8E9CEA42-6B07-467B-A75A-D9B94D1C6A28

P478

Q43245707-0D3CF0C6-BFA1-43C0-90EE-8BEAD95D7577

P577

Q43245707-165A397A-6FAE-4ACF-B1F3-9CBBF7AD2EE6

P5875

Q43245707-332122BD-C5C8-4163-AA2F-501653BDF726

P6179

Q43245707-C9D17251-9DDC-4AED-84C7-CE5053F35570

P698

Q43245707-873F2722-A563-459B-AC91-54B1368FD4E1

P921

Q43245707-36D0C67B-6B05-4F4F-9BEB-5FA9EEFC6E15

P932

Q43245707-21A3907E-C075-4D0B-9968-9BE7847AEC22

P356

P1433

British Journal of Cancer

P1476

Did animal offer relevant model for Bevacizumab testing?

@en

P2093

C Eveno

http://www.w3.org/2001/XMLSchema#string

G Tobelem

http://www.w3.org/2001/XMLSchema#string

M Pocard

http://www.w3.org/2001/XMLSchema#string

S Gaujoux

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis

Interaction between bevacizumab and murine VEGF-A: a reassessment.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

P2888

P304

1555; author reply 1556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604693

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23439561

http://www.w3.org/2001/XMLSchema#string

P6179

1035702836

http://www.w3.org/2001/XMLSchema#string

P698

18971937

http://www.w3.org/2001/XMLSchema#string

P921

P932

2579700

http://www.w3.org/2001/XMLSchema#string